A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients

The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populati...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1985-10, Vol.52 (4), p.525-529
Main Authors: Dowsett, M, Harris, A L, Stuart-Harris, R, Hill, M, Cantwell, B M, Smith, I E, Jeffcoate, S L
Format: Article
Language:English
Subjects:
Adult
Aged
Aminoglutethimide - administration & dosage
Aminoglutethimide - therapeutic use
Androstenedione - blood
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Cancer Research
Dehydroepiandrosterone - analogs & derivatives
Dehydroepiandrosterone - blood
Dehydroepiandrosterone Sulfate
Depression, Chemical
Drug Combinations
Drug Resistance
Epidemiology
Estradiol - blood
Estrone - blood
Female
Genital system. Reproduction
Humans
Hydrocortisone - therapeutic use
Medical sciences
Menopause
Middle Aged
Molecular Medicine
Oncology
original-article
Pharmacology. Drug treatments
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG + HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG + HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1985.223